| Drug Name |
Lapatinib |
| Drug ID |
BADD_D01248 |
| Description |
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. |
| Indications and Usage |
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EH01 |
| DrugBank ID |
DB01259
|
| KEGG ID |
D08108
|
| MeSH ID |
D000077341
|
| PubChem ID |
208908
|
| TTD Drug ID |
D08CDI
|
| NDC Product Code |
0078-0671; 68180-801; 61187-009 |
| UNII |
0VUA21238F
|
| Synonyms |
Lapatinib | N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine | Tykerb | GW 282974X | GW282974X | GW-282974X | GW572016 | GW-572016 | GW 572016 | Lapatinib Ditosylate |
